Literature DB >> 18220622

Pathophysiology and treatment of diabetic peripheral neuropathy: the case for diabetic neurovascular function as an essential component.

Keri A Kles1, Aaron I Vinik.   

Abstract

Worldwide, diabetes and its complications are major causes of morbidity, decreased quality of life, mortality and increasing health care costs. Patients with diabetes attempt to control blood pressure, lipids and blood glucose levels to decrease their risk of macrovascular and microvascular complications, such as diabetic peripheral neuropathy (DPN). Even with control of these risk factors for vascular disease, many patients still develop complications. Targeted therapies to the underlying mechanisms of diabetic neuropathy are essential to slow the progression of the disease. This review describes the signs, symptoms and diagnosis of DPN. Additionally, new therapies and the complex etiology that contributes to the development of diabetic neuropathy are described (oxidative stress, hyperglycemia, advanced glycated end products, autoimmunity, neurotrophic factors and protein kinase C beta).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18220622     DOI: 10.2174/157339906776818569

Source DB:  PubMed          Journal:  Curr Diabetes Rev        ISSN: 1573-3998


  21 in total

1.  Small fibre dysfunction, microvascular complications and glycaemic control in type 1 diabetes: a case-control study.

Authors:  P R J Vas; A Q Green; G Rayman
Journal:  Diabetologia       Date:  2011-12-23       Impact factor: 10.122

2.  Local sensory nerve control of skin blood flow during local warming in type 2 diabetes mellitus.

Authors:  Nicholas A Strom; Jessica R Sawyer; Shelly K Roberts; Shirley M Kingsley-Berg; Nisha Charkoudian
Journal:  J Appl Physiol (1985)       Date:  2009-12-03

Review 3.  Hyperlipidemia: a new therapeutic target for diabetic neuropathy.

Authors:  Andrea M Vincent; Lucy M Hinder; Rodica Pop-Busui; Eva L Feldman
Journal:  J Peripher Nerv Syst       Date:  2009-12       Impact factor: 3.494

4.  Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists.

Authors:  Xiaohui Du; Paul J Dransfield; Daniel C-H Lin; Simon Wong; Yingcai Wang; Zhongyu Wang; Todd Kohn; Ming Yu; Sean P Brown; Marc Vimolratana; Liusheng Zhu; An-Rong Li; Yongli Su; Xianyun Jiao; Jiwen Jim Liu; Gayathri Swaminath; Thanhvien Tran; Jian Luo; Run Zhuang; Jane Zhang; Qi Guo; Frank Li; Richard Connors; Julio C Medina; Jonathan B Houze
Journal:  ACS Med Chem Lett       Date:  2014-02-03       Impact factor: 4.345

5.  Effect of glycemic control on corneal nerves and peripheral neuropathy in streptozotocin-induced diabetic C57Bl/6J mice.

Authors:  Matthew S Yorek; Alexander Obrosov; Hanna Shevalye; Sergey Lupachyk; Matthew M Harper; Randy H Kardon; Mark A Yorek
Journal:  J Peripher Nerv Syst       Date:  2014-09       Impact factor: 3.494

6.  Identification of an Orally Efficacious GPR40/FFAR1 Receptor Agonist.

Authors:  Sameer Agarwal; Santosh Sasane; Prashant Deshmukh; Bhadresh Rami; Debdutta Bandyopadhyay; Poonam Giri; Suresh Giri; Mukul Jain; Ranjit C Desai
Journal:  ACS Med Chem Lett       Date:  2016-09-21       Impact factor: 4.345

Review 7.  Diabetic painful and insensate neuropathy: pathogenesis and potential treatments.

Authors:  Irina G Obrosova
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

8.  Discovery of a Potent and Orally Efficacious TGR5 Receptor Agonist.

Authors:  Sameer Agarwal; Amit Patil; Umesh Aware; Prashant Deshmukh; Brijesh Darji; Santosh Sasane; Kalapatapu V V M Sairam; Priyanka Priyadarsiny; Poonam Giri; Harilal Patel; Suresh Giri; Mukul Jain; Ranjit C Desai
Journal:  ACS Med Chem Lett       Date:  2015-11-20       Impact factor: 4.345

Review 9.  Vascular Impairment of Epineurial Arterioles of the Sciatic Nerve: Implications for Diabetic Peripheral Neuropathy.

Authors:  Mark A Yorek
Journal:  Rev Diabet Stud       Date:  2015-08-10

10.  Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.

Authors:  James F List; Vincent Woo; Enrique Morales; Weihua Tang; Fred T Fiedorek
Journal:  Diabetes Care       Date:  2008-12-29       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.